### STROBE Statement—Checklist of items that should be included in reports of cohort studies

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
</table>
| **Title and abstract** | 1 | *(a)* Indicate the study’s design with a commonly used term in the title or the abstract  
 *(b)* Provide in the abstract an informative and balanced summary of what was done and what was found | 1    |

**Introduction**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Background/rationale</strong></td>
<td>2</td>
<td>Explain the scientific background and rationale for the investigation being reported</td>
</tr>
<tr>
<td><strong>Objectives</strong></td>
<td>3</td>
<td>State specific objectives, including any prespecified hypotheses</td>
</tr>
</tbody>
</table>

**Methods**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study design</strong></td>
<td>4</td>
<td>Present key elements of study design early in the paper</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>5</td>
<td>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</td>
</tr>
</tbody>
</table>
| **Participants** | 6 | *(a)* Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up  
 *(b)* For matched studies, give matching criteria and number of exposed and unexposed | 7-8  |

**Variables**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Variables</strong></td>
<td>7</td>
<td>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</td>
</tr>
</tbody>
</table>

**Data sources/measurement**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data sources/measurement</strong></td>
<td>8*</td>
<td>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</td>
</tr>
</tbody>
</table>

**Bias**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bias</strong></td>
<td>9</td>
<td>Describe any efforts to address potential sources of bias</td>
</tr>
</tbody>
</table>

**Study size**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study size</strong></td>
<td>10</td>
<td>Explain how the study size was arrived at</td>
</tr>
</tbody>
</table>

**Quantitative variables**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quantitative variables</strong></td>
<td>11</td>
<td>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why</td>
</tr>
</tbody>
</table>

**Statistical methods**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
</table>
| **Statistical methods** | 12 | *(a)* Describe all statistical methods, including those used to control for confounding  
 *(b)* Describe any methods used to examine subgroups and interactions  
 *(c)* Explain how missing data were addressed  
 *(d)* If applicable, explain how loss to follow-up was addressed  
 *(e)* Describe any sensitivity analyses | 9-11 |

**Results**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
</table>
| **Participants** | 13* | *(a)* Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed  
 *(b)* Give reasons for non-participation at each stage  
 *(c)* Consider use of a flow diagram | 7-8  |

**Descriptive data**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
</table>
| **Descriptive data** | 14* | *(a)* Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders  
 *(b)* Indicate number of participants with missing data for each variable of interest  
 *(c)* Summarise follow-up time (eg. average and total amount) | 12, 22, 7-8 |

**Outcome data**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outcome data</strong></td>
<td>15*</td>
<td>Report numbers of outcome events or summary measures over time</td>
</tr>
<tr>
<td>Main results</td>
<td>16</td>
<td>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(b) Report category boundaries when continuous variables were categorized</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</td>
</tr>
<tr>
<td>Other analyses</td>
<td>17</td>
<td>Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</td>
</tr>
<tr>
<td>Discussion</td>
<td></td>
<td>Key results</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Limitations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Interpretation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Generalisability</td>
</tr>
<tr>
<td>Other information</td>
<td></td>
<td>Funding</td>
</tr>
</tbody>
</table>

*Give information separately for exposed and unexposed groups.